RYANODINE RECEPTOR INHIBITOR COMPOUNDS AND METHODS RELATING THERETO

Organization Name

Vanderbilt University

Inventor(s)

Jeffrey N. Johnston of Nashville TN (US)

Suzanne Batiste of Nashville TN (US)

Abigail N. Smith of Nashville TN (US)

Daniel J. Blackwell of Nashville TN (US)

Björn C. Knollmann of Bethesda MD (US)

RYANODINE RECEPTOR INHIBITOR COMPOUNDS AND METHODS RELATING THERETO - A simplified explanation of the abstract

This abstract first appeared for US patent application 18517872 titled 'RYANODINE RECEPTOR INHIBITOR COMPOUNDS AND METHODS RELATING THERETO

Simplified Explanation

The abstract of the patent application describes the development of RyR2 inhibitors for the treatment of cardiac conditions. RyR2 is a receptor type involved in calcium release in cardiac muscle cells, and inhibiting its activity can have therapeutic benefits.

RyR2 inhibitors are being developed for the treatment of cardiac conditions.
These inhibitors target a specific receptor type involved in calcium release in cardiac muscle cells.
Inhibiting RyR2 activity can have therapeutic benefits for various cardiac conditions.

Potential Applications

The potential applications of this technology include:

Treatment of various cardiac conditions such as arrhythmias, heart failure, and other related disorders.

Problems Solved

This technology helps in addressing the following problems:

Providing a targeted approach to treating cardiac conditions by inhibiting RyR2 activity.
Improving the efficacy of treatment for cardiac disorders.

Benefits

The benefits of this technology include:

Enhanced treatment options for patients with cardiac conditions.
Potential for improved outcomes and quality of life for individuals with heart-related issues.

Potential Commercial Applications

The potential commercial applications of this technology are:

Pharmaceutical companies developing RyR2 inhibitors for cardiac therapies.
Medical device companies incorporating RyR2 inhibitors into treatment protocols for cardiac patients.

Possible Prior Art

One possible prior art in this field could be the development of other calcium channel blockers or cardiac medications that target different pathways involved in cardiac function.

Unanswered Questions

How do RyR2 inhibitors compare to existing treatments for cardiac conditions?

RyR2 inhibitors may offer a more targeted approach compared to traditional medications, but further studies are needed to compare their efficacy and safety profiles.

What are the potential long-term effects of RyR2 inhibitors on cardiac function?

Long-term studies are required to assess the impact of RyR2 inhibitors on overall cardiac health and function over extended periods of time.

Original Abstract Submitted

Anodine receptor type 2 (RyR2) inhibitors and methods of their use in the treatment of cardiac conditions.